Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06374485
Other study ID # AU409-LEES-2021-03
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 12, 2024
Est. completion date August 28, 2026

Study information

Verified date April 2024
Source Lee's Pharmaceutical Limited
Contact Chi Leung Chiang
Phone +852 22554352
Email chiangcl@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a Phase I, dose-escalation study of AU409 in advanced hepatocellular carcinoma patients who failed standard treatment. A '3+3' dose-escalation design will be utilized to gradually increase the dose of AU409, aiming to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of multi-dose AU409 in patients with advanced HCC.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date August 28, 2026
Est. primary completion date February 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male or female of 18-75 (inclusive) years of age. 2. Patients with histologically and/or cytologically and/or radiologically confirmed advanced (unresectable or metastatic) hepatocellular carcinoma (HCC) that have failed any of standard treatment (including Immunotherapies and/or Tyrosine Kinase Inhibitor therapies, or Oxaliplatin-based systemic chemotherapies), recurrence, or are intolerant. 3. Before treatment initiation, patients must have previously completed chemotherapy, radiotherapy, interventional therapy for more than 4 weeks (except palliative radiotherapy for bone metastasis). And all treatment-related toxicities (except hair loss, pigmentation, and chemotherapy-related neurotoxicities, etc.) have recovered (= level 1 or baseline level). 4. Have at least one evaluable disease lesion based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). 5. ECOG score of 0 or 1. 6. Patients with Child Pugh class A or some class B (=7 and no hepatic encephalopathy). 7. Have a life expectancy of >12 weeks. 8. Able to be orally administered. 9. Laboratory examinations must meet the following criteria within 7 days before treatment initiation: - Absolute neutrophil count(ANC)=1.5 × 109/L,platelets(PLT) count =75 × 109/L,hemoglobin(HGB)=90 g/L,and patients are not allowed to receive blood transfusion or other haematopoietic growth factors within 14 days before treatment initiation. - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be =5.0×upper limit of normal (ULN). - Total bilirubin (TBIL) =1.5×ULN. - Ablumin (ALB) =28g/L. - Serum creatinine (CRE) =1.0×ULN, creatinine clearance rate (CCR) =60 mL/min (Cockcroft-Gault equation). - International normalized ratio(INR)=1.5,prothrombin time (PT) =1.5×ULN. 10. Have a negative serum pregnancy test for premenopausal women (postmenopausal women who have been menopausal for at least 12 months are considered as infertile). For male patients (including male patients' female spouses of child-bearing potential) and female patients of child-bearing potential must be contraceptive throughout the study and within the 6 months following the last dose of AU409. 11. Patients voluntarily give written informed consent form (ICF). Exclusion Criteria: 1. Patients of central nervous system metastasis with clinical symptoms (except patients who are asymptomatic, and no disease progression confirmed by MRI diagnosis for more than 28 days). 2. Allergies to any ingredients or excipients in AU409. 3. Treatment with other anticancer therapies (including surgery, radiation therapy, chemotherapy, anti-angiogenic therapy, targeted therapy, or radiofrequency ablation therapy, etc.) or investigational therapy (except patients who stop treatment of Chinese patent medicine or Chinese herbal medicine for more than 7 days, or complete palliative radiotherapy for bone metastasis >2 weeks) within 28 days prior to the first dosing. 4. QTc =470 msec during screening period (Fridericia's equation) or with a history of congenital long QT syndrome. 5. Patients with history of gastrointestinal surgery that may change the absorption and activity of drugs in their body (such as total gastrectomy, small bowel resection, external bile shunt, etc.) in combination with refractory hiccups, nausea, vomiting, and other diseases that affect drug absorption (such as peptic ulcer, inflammatory bowel disease, lactose intolerance, malabsorption syndrome or chronic diarrhea, etc.). 6. Patients who require serous effusion for continuous drainage or drug infusion (such as ascites, pleural effusion, etc.), or have undergone portal vein shunt. 7. Patients with gastrointestinal perforation and/or fistula, abdominal abscess, visceral fistula, intestinal obstruction, hepatic encephalopathy, portal vein and inferior vena cava cancer thrombus within 3 months prior to the treatment initiation. 8. Patients have gastrointestinal bleeding (including esophageal or gastric varices, local active ulcer lesions, etc.), or have a clear bleeding tendency, or are receiving anticoagulation/thrombolytic therapy within 3 months before treatment initiation. Positive result of occult blood needs to identifythe causes. 9. Patients with interstitial lung disease, non-infectious pneumonia. 10. History of allogeneic stem cell transplantation or organ transplantation. 11. Patients who receive major surgery (except biopsy and puncture) or with major trauma within 28 days before treatment initiation. 12. Patients with infectious diseases that affect daily activities or require systemic treatment (such as the use of hormones, antibiotics, antifungal drugs, antiviral drugs, and oxygen inhalation), including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc. 13. Uncontrolled diseases, including a) New York Heart Association (NYHA) Class II or higher heart failure, b) Severe/unstable angina pectoris, c) Primary cardiomyopathy, d) Myocardial infarction or coronary/peripheral artery bypass surgery occurred within 6 months before treatment initiation, e) Uncontrollable high blood pressure, f) Severe arrhythmia requiring medication or intervention, g) Echocardiographic left ventricular ejection fraction <50% during the screening period, h) Deep vein thrombosis/arterial thrombosis /Pulmonary vein embolism occurred within 2 months before treatment initiation, i) Cerebrovascular accident or transient ischemic attack occurred within 6 months before treatment initiation, j) Ocular lens disease (such as cataract), k) Diabetes that has not been effectively controlled, l) Thyroid diseases that have not been effectively controlled, m) Urine protein=2+ and quantity of 24-hour urine protein =1.0g. 14. Human immunodeficiency virus infection (HIV 1/2 antibody positive). 15. HBV infection (HBsAg positive and HBV DNA =2000 IU/mL); Hepatitis C virus (HCV) antibody is positive and HCV RNA>103 copies/ml; HBsAg and HCV antibodies are both positive. 16. Patients with tuberculosis (TB) who need to receive/are receiving anti-TB treatment within 1 year before treatment initiation. 17. Pregnant or nursing; 18. Patients complicated with other malignant tumors within 5 years before treatment initiation, except various in situ tumors, skin basal cell carcinoma or squamous cell carcinoma that have been cured in the past, local prostate cancer receiving radical operation, and in situ breast ductal carcinoma receiving radical operation. 19. Patients with other severe, acute, chronic, or psychiatric illnesses that may increase the risk of treatment or may interfere with interpretation of the trial results. And patients with alcoholism, smoking addiction, drug abuse, and other circumstances that are not conductive to the treatment or explain adverse events, thereby contributing to decrease study compliance. 20. Other conditions that are not suitable for participating in the study in the opinion of investigator. 21. Patients who were treated with pentamidine prior to treatment initiation or during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AU409 capsules
Oral administration

Locations

Country Name City State
China Department of Clinical Oncology, Queen Mary Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity To determine the maximum tolerated dose (MTD) and the recommended phase II dose (R2PD). At the end of Cycle 1 (each cycle is 28 days)
Secondary Maximum Tolerated Dose If 2 or more out of 3 or 6 patients at a dose level develop DLTs, the dose will be considered as "intolerable dose", and the preceding dose level is defined as the Maximum Tolerated Dose (MTD). Through study completion, an average of 2 years
Secondary Recommended Phase 2 Dose RP2D will be determined in accordance with occurrence of the DLTs and AEs. Through study completion, an average of 2 years
Secondary Objective Response Rate The proportion of patients whose best efficacy is CR and PR observed throughout the study from enrollment to disease progression. Through study completion, an average of 2 years
Secondary Disease Control Rate The proportion of patients whose best efficacy is CR, PR, and SD throughout the study from enrollment to disease progression. Through study completion, an average of 2 years
Secondary Duration of Response The time from the first tumor evaluation as CR or PR to the first evaluation as PD or death from any cause during the study. Through study completion, an average of 2 years
Secondary Progression-free Survival The time from enrollment until the disease progression or death from any cause. Through study completion, an average of 2 years
Secondary Overall Survival The time from enrollment to death from any cause. Through study completion, an average of 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT05057845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT02638857 - Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT02632006 - Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT00752063 - Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma Phase 2
Completed NCT00517920 - Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT05797805 - A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Active, not recruiting NCT05070156 - B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Early Phase 1
Not yet recruiting NCT06092112 - A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma Early Phase 1
Recruiting NCT01214343 - Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC Phase 3
Completed NCT00999882 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients Phase 1
Withdrawn NCT00756782 - A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT00534664 - Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04503902 - Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Terminated NCT04777708 - BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Early Phase 1
Completed NCT04072679 - Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma Phase 1
Suspended NCT04066660 - Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) N/A
Withdrawn NCT05592197 - Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT N/A
Completed NCT02528643 - A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1